AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Bempedoic Acid versus Ezetimibe and 3-Year Cardiovascular Outcomes in Statin-Intolerant Adults with Hyperlipidemia

By Khan ZZ, Sajid A, Khan FZ et al.

Background: Bempedoic acid and ezetimibe are both used as non-statin lipid-lowering options in patients with hyperlipidemia and statin intolerance, but real-world comparative data on clinical outcomes are limited. Hypothesis: Among adults with hyperlipidemia and statin intolerance, bempedoic acid is associated with different 3-year cardiovascular outcomes than ezetimibe. Methods: Retrospective propensity score-matched cohort study in the TriNetX US Collaborative Network (67 healthcare organizations). Adults with hyperlipidemia and statin intolerance who initiated bempedoic acid were compared with those who initiated ezetimibe. Propensity score matching was comprehensive: cohorts were balanced 1:1 across demographics, diagnoses, medications, and laboratory values, yielding well-balanced groups of 20,985 each (all standardized mean differences below 0.10 after matching; for example, baseline atorvastatin use balanced from a standardized mean difference of 0.29 to 0.01). Outcomes were assessed over 1,095 days. Risk ratios (RR) were derived from event proportions; hazard ratios (HR) used Cox models with log-rank p-values. Results: Compared with ezetimibe, bempedoic acid was associated with lower 3-year all-cause mortality (2.0% vs 3.3%; RR 0.62, 95% CI 0.55-0.70; HR 0.56, 0.50-0.63; P<0.001) and lower 3-point MACE (10.8% vs 12.3%; RR 0.88, 0.83-0.92; HR 0.81, 0.76-0.85; P<0.001). Safety signals were more frequent with bempedoic acid: new or worsening gout (3.7% vs 3.0%; RR 1.21, 1.09-1.34; HR 1.12, 1.01-1.24; P=0.040) and creatine kinase elevation (10.4% vs 9.2%; RR 1.13, 1.07-1.20; P<0.001). Attainment of LDL-C below 70 mg/dL was lower with bempedoic acid (22.6% vs 26.7%; RR 0.85, 0.82-0.88; P<0.001). By risk ratio, no significant differences were seen for acute myocardial infarction (RR 0.94; P=0.098), ischemic stroke (RR 0.96; P=0.355), coronary revascularization (RR 1.11; P=0.138), or tendon injury (RR 1.11; P=0.161); however, survival analysis favored bempedoic acid for myocardial infarction (HR 0.87; log-rank P=0.001) and stroke (HR 0.89; log-rank P=0.011). Conclusions: In comprehensively propensity-matched adults with hyperlipidemia and statin intolerance, bempedoic acid was associated with lower mortality and MACE than ezetimibe, accompanied by higher rates of gout and creatine kinase elevation. These hypothesis-generating findings warrant prospective head-to-head evaluation.

doi.org/10.1161/circ.154.suppl_1.17612Interventions

AgingResearch.News